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p270 is an integral member of human SWI-SNF complexes, first identified through its shared antigenic
specificity with p300 and CREB binding protein. The deduced amino acid sequence of p270 reported here
indicates that it is a member of an evolutionarily conserved family of proteins distinguished by the presence
of a DNA binding motif termed ARID (AT-rich interactive domain). The ARID consensus and other structural
features are common to both p270 and yeast SWI1, suggesting that p270 is a human counterpart of SWI1. The
approximately 100-residue ARID sequence is present in a series of proteins strongly implicated in the
regulation of cell growth, development, and tissue-specific gene expression. Although about a dozen ARID
proteins can be identified from database searches, to date, only Bright (a regulator of B-cell-specific gene
expression), dead ringer (a Drosophila melanogaster gene product required for normal development), and
MRF-2 (which represses expression from the cytomegalovirus enhancer) have been analyzed directly in regard
to their DNA binding properties. Each binds preferentially to AT-rich sites. In contrast, p270 shows no
sequence preference in its DNA binding activity, thereby demonstrating that AT-rich binding is not an intrinsic
property of ARID domains and that ARID family proteins may be involved in a wider range of DNA interactions.
SWI-SNF complexes were first identified in yeast cells,
where they are involved in the regulation of an array of induc-
ible genes including those required for the mating type switch
and sucrose fermentation pathways (16, 28). More-recent stud-
ies suggest that these complexes have a more general role in
the regulation of gene expression. The isolation and charac-
terization of Drosophila melanogaster and mammalian ho-
mologs of many of the yeast complex members suggest that
SWI-SNF complexes play fundamental roles in the regulation
of gene expression during cell growth and development in all
organisms (reviewed in reference 14; 17).
Although SWI-SNF complexes have demonstrated DNA
binding capabilities (29), the source of this activity in the com-
plexes remains unclear. The only DNA binding protein iden-
tified to date in mammalian SWI-SNF complexes is BAF-57,
which has a DNA binding activity restricted to four-way junc-
tion DNA. SWI-SNF complexes lacking a functional BAF-57
retain DNA binding activity, indicating that other DNA bind-
ing components must be present (41).
p270 is an integral member of human SWI-SNF complexes,
first identified through its shared antigenic specificity with p300
and CREB binding protein (CBP) (5, 6). The p300/CBP/p270
cross-reactive antibodies coprecipitate a series of proteins that
includes the mammalian SWI-SNF complex components
BRG1, BAF-170, BAF-155, and hSNF5/Ini1. Conversely, an-
tibodies directed against the individual human SWI-SNF com-
plex components BRG1 and BAF-155 immunoprecipitate
p270, as demonstrated by reactivity with a p270-specific anti-
body (6). The sequence of p270 described here indicates that
this protein contains a highly conserved DNA binding region
termed the AT-rich interactive domain, or ARID, first recog-
nized in the murine Bright and the Drosophila dead ringer
(DRI) gene products (9, 11). The approximately 90-residue
ARID sequence is present in a series of proteins strongly
implicated in the regulation of cell growth, development, and
tissue-specific gene expression (see Table 1). Bright is a regu-
lator of B-cell-specific gene expression (11, 42), and DRI is a
corepressor for dorsal, is implicated in the activation or repres-
sion of other transcriptional regulators, and is required for
normal Drosophila development (9, 32, 37). The diverse array
of regulatory proteins that contain an ARID consensus (re-
viewed in reference 19) includes the yeast SWI1 protein, a
component of yeast SWI-SNF complexes that has been found
to cross-link with DNA in vitro (29).
At present, more than a dozen ARID-bearing proteins can
be identified from database sequences. However, only Bright,
DRI, and MRF-2, a cytomegalovirus (CMV) enhancer binding
protein, have been characterized directly in regard to their
DNA binding properties. Bright binds to matrix attachment
regions, which are highly AT-rich stretches of about 20 to 40
bases (11). DRI binds to a core ATTA motif similar to that
present in homeodomain sites (9). MRF-2 binds preferentially
to the sequence AATAC/T in binding site selection assays (43).
While the properties of these proteins have suggested that
ARIDs have intrinsic specificity for AT-rich sequences (albeit
of somewhat different compositions), analysis of p270 indicates
that sequence specificity is not intrinsic to the core ARID
motif. p270 binds native duplex DNA in an ARID sequence-
dependent manner but shows no discernible sequence prefer-
ence in its DNA binding activity, indicating that DNA binding
via ARID regions is not restricted to AT-rich sequences and
consistent with suggestions that ARID family proteins are in-
volved in a wider range of DNA interactions. The presence of
a recognized DNA binding domain in p270 and the demon-
strated ability of p270 to bind linear duplex DNA suggest that
p270 contributes to the DNA binding activity in the SWI-SNF
complex.
* Corresponding author. Mailing address: Fels Institute for Cancer
Research and Molecular Biology, Temple University School of Med-
icine, Philadelphia, PA. Phone: (215) 707-7313. Fax: (215) 707-6989.
E-mail: betty@unix.temple.edu.
† Present address: Institute for Child Health Research, University of
Western Australia, West Perth, Western Australia, Australia.
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MATERIALS AND METHODS
cDNA isolation. p270 was gel purified and subjected to peptide microsequence
analysis as described in reference 6. The R29 peptide (pep29) (sequence shown
in Fig. 1) was used to generate p270-specific rabbit antiserum (rabbit 67). A
human HeLa lgt11 cDNA expression library (Clontech) randomly primed with
oligo(dT) was screened with rabbit 67 antiserum using standard procedures. An
insert from a positive clone identified in this initial screening process was then
used to screen a human HeLa lZAPII oligo(dT)-primed cDNA library (Strat-
agene) by DNA hybridization, which yielded a clone containing approximately
2.5 kb of 39 cDNA sequence. A 59-rapid amplification of cDNA ends (59-RACE)
procedure was used to extend the 2.5-kb cDNA sequence. Total RNA obtained
from WI-38 cells was subjected to sequential rounds of extension using a 59-
RACE kit in accordance with the manufacturer’s instructions (Gibco BRL).
After two rounds of nested PCR (Expand high-fidelity PCR system; Boehringer-
Mannheim) using gene-specific primers and primers provided with the kit, the
amplified products were digested with appropriate restriction enzymes and
cloned into appropriate plasmid vectors. DNA sequence data were obtained
from both strands of plasmid templates using both the fmol cycle sequencing
system (Promega) and automated DNA sequencing procedures. Approximately
50% of the sequence could be confirmed by expressed sequence tag (EST)
sequences already present in the data banks.
Northern blots. Multiple-tissue Northern blots (Clontech) were screened with
a 2.5-kb cDNA fragment spanning the 39 terminus of the coding sequence for
p270 (nucleotides 3678 to 6200). The probe was labeled by random priming with
[a-32P]dATP. Hybridization and washing conditions were as described by the
supplier.
Computer analysis. DNA sequence compilation and open reading frame anal-
ysis were undertaken using programs of the Genetics Computer Group (GCG)
sequence analysis software package (Madison, Wis.). The GCG Prettybox pro-
gram was used to generate the alignment of the ARID motifs. Database amino
acid sequence comparisons were undertaken using the BLASTp program with
the low-complexity filtering option (2).
In vitro translation and DNA cellulose chromatography. p270 cDNA frag-
ments in appropriate plasmid vectors were used to generate [35S]methionine-
labeled polypeptides using the TNT coupled-reticulocyte system (Promega). In
vitro-translated p270 cDNA plasmid constructs used in this study include pPE14
(p270603–1927; encoding amino acids 603 to 1927), p110 (p2701237–1927), pNNE3
(p270543–1018), pMY6 (p270678–1018), and pNE9WY (p270543–1281 containing ala-
nine substitutions at positions 715 and 738). In vitro-translated proteins were
applied to native DNA cellulose columns (Pharmacia) equilibrated in loading
buffer (10 mM potassium phosphate [pH 6.2], 0.5% NP40, 10% glycerol, 1 mM
dithiothreitol [DTT], aprotinin [1 mg/ml], 50 mM NaCl); the bed volume was
approximately 1 ml. The column was washed four times with 0.5 bed volumes of
loading buffer and eluted stepwise with loading buffer adjusted to contain in-
creasing concentrations of NaCl as indicated below. Aliquots of the flowthrough
and each fraction were analyzed by sodium dodecyl sulfate (SDS)-polyacryl-
amide gel electrophoresis or in a nitrocellulose filter binding assay in a standard
slot blot apparatus. Quantification was performed using a phosphorimager (Fuji)
and associated software.
GST fusion proteins. pNDX was generated by cloning a p270 cDNA fragment
encoding residues 600 to 1018, containing the p270 ARID and flanking se-
quences, into pGEX4T3 (Pharmacia) to make a glutathione S-transferase
(GST) fusion protein construct (GSTp270600–1018). The DRI plasmid p410
(GST-dri258–410) (9) (kind gift from R. Saint, University of Adelaide, South
Australia, Australia) has been described previously. Fusion proteins were pro-
duced in Escherichia coli strain BL21 after induction with 1 mM IPTG (isopro-
pyl-b-D-thiogalactopyranoside) and growth at 30 (GSTp270600–1018) or 37°C
(GST-dri258–410). Fusion proteins were purified on glutathione-Sepharose beads
using standard procedures.
Generation of amino acid substitution mutations. Amino acid substitution
mutants were generated using the QuikChange (Stratagene) system according to
the manufacturer’s instructions. The forward primer used to generate the
Tyr3Ala substitution had the sequence CCTTGAAAAAGCAGGCTATCCAG
TGTCTCTATGC. The forward primer used to generate the Trp3Ala substitu-
tion had the sequence GGTCAACAAGAACAAAAAAGCGCGGGAACTTG
CAACC. The substituted bases in each primer are underlined. The sequence
changes and the integrity of the surrounding sequence were verified by DNA
sequencing.
PCR-assisted DNA binding selection from random oligonucleotides. The
GSTp270600–1018 fusion protein was used to determine the sequence specificity of
the p270 ARID using PCR-assisted selection and amplification. A mixture of
50-base oligonucleotides, in which the middle 20 bases consisted of random
nucleotides, was converted to double-stranded oligonucleotides by PCR, using
32P-end-labeled primers 1 (59-GTACCCGGGGATCCT-39) and 2 (59-TTGCA
TGCCTGCAGG-39) complementary to the flanking sequences in the 50-mers.
Approximately 100 ng of double-stranded oligonucleotides was suspended in 250
ml of binding buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 0.5 mM EDTA,
10% glycerol, 1 mM DTT, 20 mg of bovine serum albumin (BSA)/ml, 2 mg of
poly[dI-dC]/ml) and applied to approximately 100 ng of GSTp270600–1018 fusion
protein attached to 10 ml of glutathione-Sepharose beads equilibrated in binding
buffer. The mixture was rotated at 4°C for 1 h and then was centrifuged at
12,000 3 g for 1 min. The supernatant was removed, and the pellet was washed
twice with 1 ml of binding buffer with either 100 or 800 mM NaCl. This pellet was
resuspended in 30 ml of water, boiled for 3 min, and centrifuged rapidly. This
supernatant was digested with proteinase K for 3 h and extracted with phenol-
chloroform, and the DNA was amplified by PCR with primers 1 and 2. The
amplified DNA was gel purified and reapplied to the fusion protein–glutathione-
Sepharose bead mixture. After four (for 100 mM NaCl washes) or six (for 800
mM NaCl washes) sequential cycles of elution, amplification, and reapplication,
the double-stranded, gel-purified oligonucleotides were digested with BamHI
and PstI, cloned into plasmid vectors, and sequenced.
EMSA. The DNA binding specificities of p270 and DRI were examined by
electrophoretic mobility shift assay (EMSA) using purified GSTp270600–1018 and
GST-dri258–510 fusion proteins. Approximately 100 ng of fusion protein was
incubated with 32P-labeled double-stranded PCR product (approximately 2 3
104 cpm) in 10 mM Tris (pH 7.5)–200 mM KCl–1 mM EDTA–0.2 mM DTT–
10% glycerol–50 mg of BSA/ml at 30°C for 30 min. Poly(dI-dC) was added to
individual reaction mixtures before incubation as indicated below. After electro-
phoresis on 5% acrylamide gels in Tris-glycine buffer, the gels were dried and
autoradiographed. The sequences of the ;20-bp inserts in the probes are as
follows: dri.16, CATCAATAAATTAGAATTAA; p270.18, ACCGGGGGTGC
CACACCGTTGA.
RESULTS
Peptide sequencing and isolation of p270 cDNA. p270 was
originally detected as a novel protein recognized by the p300-
reactive monoclonal antibody NM1. Analysis of NM1 immune
complexes indicated that p270 is an integral component of
mammalian SWI-SNF complexes (5, 6). In order to character-
ize this protein further, p270 was isolated and purified to ob-
tain the peptide sequence. Four p270 peptides obtained from
this analysis are shown in Fig. 1. The sequence of peptide 29
was used to generate a synthetic peptide and raise rabbit an-
tipeptide antibodies (rabbit 67). These antibodies recognize
p270 specifically in NM1-, BRG1-, or BAF-155-specific im-
mune precipitations (6). The rabbit 67 antibody was used to
screen a HeLa cDNA expression library randomly primed with
oligo(dT), which yielded a 650-bp fragment encoding a se-
quence that matched p270 peptide 29 in 12 of 13 residues. The
fragment also contained a sequence encoding matches to two
other peptides, pep20 and pep31, in the same open reading
frame. This fragment was used to screen a second HeLa cDNA
library. Several overlapping cDNAs were isolated, including a
2.5-kb clone containing additional cDNA sequences 59 and 39
to the original 650-bp fragment. The 2.5-kb fragment included
a sequence encoding the pep17 peptide and contained a con-
sensus polyadenylation signal (AATAAA) and a poly(A) tail.
The cDNA hybridized to RNA species migrating at approxi-
mately 8.0 kb (Fig. 2), consistent with the expected size of the
p270 mRNA. We concluded that the 2.5-kb fragment encoded
an authentic p270 sequence and included the 39 terminus of
FIG. 1. Sequences of peptides obtained from the microsequencing of p270.
Left column, sequences of four peptides derived from the peptide sequencing of
gel-purified p270 isolated from human cells; middle column, sequence of the
multiple-antigen peptide (map) that was used to raise the p270-specific antibod-
ies used in the cloning; right column, sequences of the corresponding regions
deduced from the p270 cDNA clone, with the position number of the initial
residue indicated for reference to Fig. 3. X represents uncertainty in reading the
protein sequence. The underlining indicates a single discrepancy between the
sequence obtained by direct sequencing and that obtained by sequencing the
cDNA.
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the p270 cDNA. In addition, as expected from the broad dis-
tribution patterns of other components of the SWI-SNF com-
plexes, p270 expression was detected in all tissues examined
(Fig. 2).
A 59-RACE procedure on human WI-38 cell total RNA was
used to extend the cDNA sequence. Successive rounds with
this procedure yielded a total of 6.2 kb of sequence with an
open reading frame encoding 1,927 amino acid residues. The
59 terminus of this cDNA sequence is strikingly GC rich, which
prevents analysis of the extreme N-terminal sequence. From its
relative migration in protein gels, we estimate that p270 con-
tains approximately 2,000 amino acid residues, which suggests
that the clone we have is over 95% complete. This large clone
reveals a number of structural features as discussed below. The
sequence of the p270 clone and the deduced sequence of the
corresponding open reading frame are shown in Fig. 3.
p270 is an ARID protein family member structurally related
to yeast SWI1. A filtered ungapped BLAST search program (2,
3) was used to search for proteins showing relationships to
p270. This program identified several proteins with a statisti-
cally significant degree of relationship to p270, including p300.
Other proteins with significant homology to p270 include (i) a
cDNA product (B120) whose coding sequence was cloned as
part of a search for genes containing multiple CAG repeats
(34) (accession no. AB001895) and whose sequence appears to
be a portion of the p270 sequence, but whose coding sequence
differs from our sequence at the 59 terminus and contains a
frameshift that gives rise to a truncated-p270-encoding open
reading frame; (ii) eyelid (eld), also referred to as osa, a ubiq-
uitously expressed protein involved in embryonic growth and
differentiation in Drosophila (36, 38), and (iii) a product of a
Caenorhabditis elegans cDNA sequence (YK7C8.5; GenBank
accession no. U80439) which appears from its overall degree of
sequence relationship to be an authentic C. elegans homolog of
p270 but which has not yet been ascribed any function (44).
Most of the proteins with structural relationships to p270 have
in common a recently described DNA binding motif termed
ARID (9, 11). Proteins with ARID regions include human and
murine Bright, Drosophila DRI and its human homolog
DRIL1 (18), the CMV enhancer binding proteins MRF-1 and
MRF-2, eyelid, retinoblastoma binding proteins (RBP) 1 and
2, and yeast SWI1 (p300 does not contain an ARID motif). A
comparison of the ARID region from p270 with those of other
ARID-containing proteins is shown in Fig. 4. The functions of
the known ARID proteins are listed in Table 1. Outside of the
ARID regions, proteins in this list are not generally homolo-
gous to one another.
p270 does show an interesting degree of relationship with
Drosophila eyelid, a protein involved in development, including
embryonic segmentation and photoreceptor differentiation
(36, 38). Like p270, eyelid is a large protein (2,715 residues)
and contains an ARID consensus sequence. In addition to the
ARID region, p270 and eyelid have a high degree of identity at
their C termini. Residues 1277 to 1371 of the 1,927 residues
encoded by the p270 gene open reading frame show 46%
identity to eyelid residues 1768 to 1862. Another stretch, con-
sisting of residues 1599 to 1809 in p270 and residues 2170 to
2384 in eyelid shows 48% identity. Two sets of human EST
sequences present in the data banks were proposed by Treis-
man et al. (36) to be potential human homologs of eyelid; p270
is the origin of one of these EST sequences. However, the high
degree of identity between p270 and eyelid does not extend to
sequences N-terminal of the ARID region.
We were particularly interested by the appearance of yeast
SWI1 (ADR6) (25, 27) in the list of proteins showing a rela-
tionship to p270. Our initial characterization of p270 shows
that p270 is an integral member of human SWI-SNF com-
plexes (6). Human homologs of yeast SWI2, SWI3, and SWP73
and SNF5 are known (23, 24, 39, 40), but a homolog of SWI1
has not previously been identified. Computer comparisons do
not identify significant stretches of sequence homology be-
tween p270 and SWI1 outside of the ARID regions. However,
a schematic comparison of p270 and SWI1 (Fig. 5) reveals
additional shared, potentially functional motifs. Both contain
Q-rich regions. Such regions have been implicated in transac-
tivation functions (31). Both also contain multiple copies of
amino acid motif LXXLL, which has been shown to be critical
for the binding of a variety of nuclear proteins to liganded
nuclear hormone receptors (10). The presence of p270 in hu-
man SWI-SNF complexes, combined with the ARID motif and
other sequence similarities shared by p270 and SWI1, suggests
that p270 is a human counterpart of the yeast SWI1 product.
p270 contains an ARID-dependent DNA binding activity. To
assess the DNA binding ability of p270, in vitro-translated,
35S-labeled p270 peptides were applied to native DNA cel-
lulose columns (Fig. 6). Initially, we tested p270 peptide
p270603–1927 consisting of residues 603 to 1927 of the 1,927-
residue open reading frame product. This peptide contains an
intact ARID region and was retained on the column with an
elution peak in the 400 mM fractions (Fig. 6, upper panel).
Related peptide p2701237–1927 is N-terminally truncated rela-
tive to p270603–1927. It retains the LXXLL motifs but not the
ARID region. This peptide showed no ability to bind native
DNA; it passed through the column and was recovered in the
wash fractions (Fig. 6 lower panel).
To test more specifically the relationship between the ARID
region and p270 DNA binding activity, we constructed and
tested additional peptides. Fractions from the DNA cellu-
lose columns were assessed in a filter binding assay to facil-
itate quantification of the DNA binding activity. Peptide
p270543–1018 contains the entire ARID region, which extends
from approximately residue 655 to residue 746. This smaller
peptide was retained on the DNA cellulose column with es-
sentially the same affinity as the longer peptide p270603–1927
and showed an elution peak in the 400 mM fractions (Fig. 7,
upper panel). The peptide p270678–1018 is N-terminally trun-
cated relative to p270543–1018. As a result of this truncation, the
ARID region is incomplete, missing the first 23 of the 91
residues that span the core consensus sequence. The resultant
peptide is almost completely devoid of DNA binding activity.
FIG. 2. Hybridization of p270 cDNA sequence with an ;8.0-kb RNA band in
multitissue Northern blots. Blots were probed with a 2.5-kb cDNA correspond-
ing to the 39 terminus of the p270 mRNA. Molecular sizes (left) are according to
the measurements provided by the supplier. INT, intestine; PBL, peripheral
blood lymphocytes; SKEL. MUSC., skeletal muscle.
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FIG. 3. DNA sequence and deduced amino acid sequence of human p270. The nucleotide sequence of the human p270 cDNA is represented along with the deduced
amino acid sequence of the product of the 5,781-bp open reading frame. The four LXXLL motifs and the ARID motif are underlined. Two Q-rich regions are present,
spanning residues 45 to 253 and 969 to 1072. The sequence also includes a series of seven CAG repeats (34) indicated by underlining beginning at nucleotide 2907.
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Like p2701237–1927, it is recovered almost entirely in the wash
fractions (Fig. 7, middle panel). Quantification of the counts
per minute recovered in respective fractions is indicated in the
legend to Fig. 7.
The requirement for the ARID region in the DNA binding
function was also tested by analysis of amino acid substitution
mutations. Two of the most highly conserved amino acids in
the core ARID motif are the tryptophan at position 715 in the
p270 sequence (Fig. 3 and 4) and the tyrosine at position 738.
Site-directed mutagenesis was used to show that each of these
FIG. 3—Continued.
VOL. 20, 2000 DNA BINDING PROPERTIES OF THE SWI-SNF COMPONENT p270 3141
 o
n
 January 31, 2014 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
FI
G
.
4.
A
co
m
pa
ri
so
n
of
th
e
A
R
ID
re
gi
on
s
fr
om
p2
70
w
ith
th
os
e
of
ot
he
r
A
R
ID
-c
on
ta
in
in
g
pr
ot
ei
ns
.T
he
bo
un
da
ri
es
of
th
e
A
R
ID
re
gi
on
w
er
e
or
ig
in
al
ly
de
fin
ed
in
B
ri
gh
ta
nd
D
R
I
(9
,1
1)
.T
he
se
se
qu
en
ce
s
ar
e
al
ig
ne
d
he
re
to
ge
th
er
w
ith
ot
he
rs
m
or
e
re
ce
nt
ly
ad
de
d
to
th
e
da
ta
ba
se
.B
la
ck
bo
xe
s,
id
en
tic
al
re
si
du
es
;g
ra
y
bo
xe
s,
co
ns
er
va
tiv
e
di
ffe
re
nc
es
.T
he
co
ns
en
su
s
se
qu
en
ce
co
ns
is
ts
of
36
hi
gh
ly
co
ns
er
ve
d
re
si
du
es
w
ith
an
ap
pr
ox
im
at
el
y
95
-
re
si
du
e
st
re
tc
h.
A
ll
se
qu
en
ce
sw
er
e
ob
ta
in
ed
fr
om
pu
bl
ic
pr
ot
ei
n
da
ta
ba
se
s.
A
cc
es
si
on
nu
m
be
rs
ar
e
as
fo
llo
w
s,
ey
el
id
,A
F0
53
09
1;
SW
I1
,P
09
54
7;
B
ri
gh
t,
U
60
33
5;
D
R
IL
1,
U
88
04
7;
D
R
I,
U
62
54
2;
R
B
P
1,
P2
93
74
;R
B
P
2,
P2
93
75
;
M
R
F-
1,
S2
79
62
;M
R
F-
2,
S2
79
63
;s
m
cx
,P
41
22
9;
ju
m
on
ji,
U
57
59
2;
A
ra
bi
do
ps
is
th
al
ia
na
op
en
re
ad
in
g
fr
am
e
(O
R
F)
pr
od
uc
tf
22
02
.2
0,
A
A
C
83
07
1;
C
.e
le
ga
ns
O
R
F
pr
od
uc
ts
c0
1g
8
an
d
t2
3d
8,
U
80
43
8
an
d
Z
81
12
8,
re
sp
ec
tiv
el
y.
3142 DALLAS ET AL. MOL. CELL. BIOL.
 o
n
 January 31, 2014 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
residues was changed to an alanine in a background construct
expressing residues 543 to 1281. The wild-type p270543–1281
peptide showed the same DNA binding affinity as the other
ARID-containing peptides tested, with a peak elution in the
400 mM fractions (not shown). Individually, each of the sub-
stitutions resulted in a partial impairment of DNA binding
activity (not shown). In combination, these two substitutions
almost completely abrogated the DNA binding activity of the
p270 peptide (Fig. 7, lower panel; quantification is reported in
the legend).
The marked effect of the limited deletion or of the two
single-amino-acid changes in the p270 ARID domain on the
DNA binding activity of p270 supports the conclusion that the
DNA binding activity observed in p270 derives from the pres-
ence of the ARID consensus. Analysis with p270-specific an-
tibodies of fractions from whole-cell lysates passed over native
DNA cellulose columns showed p270 eluting with a profile
similar to that seen with the in vitro-translated ARID-contain-
ing peptides (not shown).
The p270 ARID region does not show a preference for AT-
rich sequences. To determine whether the ARID region of
p270 has sequence-specific DNA binding activity, a GST fusion
protein containing p270 residues 600 to 1018, GSTp270600–1018,
was subjected to a PCR-based selection and amplification pro-
cedure directly analogous to that used to assess the DNA
binding properties of DRI. Before beginning the PCR selec-
tion, we first verified that the GST modification does not ab-
rogate the DNA binding activity of the p270 peptide. The p270
fusion protein was eluted from the glutathione-Sepharose
beads, passed over a DNA cellulose column, and collected in a
series of increasing salt fractions in the manner described
above. Aliquots of each fraction were separated on SDS-poly-
acrylamide gels. The electrophoresed proteins were trans-
FIG. 5. Alignment of p270 and SWI1. p270 and SWI1 have an overall simi-
larity of structure, in that they both contain ARID regions and they both have
multiple LXXLL motifs (which are implicated in binding to nuclear hormone
receptors), as well as Q-rich regions, which are often associated with transacti-
vation regions. SWI1 has an unusual asparagine- and threonine-rich stretch near
the N terminus; we do not yet know if this feature also occurs in p270. Other than
these common features, p270 and SWI1 do not show direct sequence homology.
FIG. 6. DNA binding activity in p270. Reticulocyte lysate-translated 35S-
labeled p270 peptides were applied to native DNA cellulose columns. The
columns were washed with loading buffer and then with increasing salt concen-
trations. Aliquots of the flowthrough (FT), wash, and eluted fractions were
analyzed on SDS gels and visualized by autoradiography. A p270 peptide en-
compassing residues 603 to 1927 and containing an intact ARID region was
retained on the column (upper panel). A related peptide, encompassing residues
1237 to 1927, with the ARID domain deleted, passed through the column and
was recovered primarily in the flowthrough and wash fractions (lower panel).
The sequences encompassed by the p270 peptides are indicated schematically to
the left of the gels.
FIG. 7. ARID-dependent DNA binding activity in p270. Reticulocyte lysate-
translated 35S-labeled p270 peptides were applied to native DNA cellulose col-
umns and eluted as described for Fig. 6. Aliquots of the flowthrough (FT), wash,
and eluted fractions were analyzed in a protein filter binding assay and visualized
by autoradiography. The sequences encompassed by the p270 peptides are indi-
cated schematically to the left of the gels. The parallel lines in the bar corre-
sponding to the peptide comprising residues 523 to 1281 represent the two
single-residue substitutions at positions 715 and 738. The elution profiles were
quantified by phosphorimaging. With the p270543–1018 peptide (upper panel),
31.3% of the total counts per minute were recovered in the flowthrough and
wash fractions, while 45.4% eluted in the 200 to 600 mM salt fractions. With
peptide p270678–1018 (middle panel), 95.3% of the total counts per minute were
recovered in the flowthrough and wash fractions while 2.28% eluted in the 200
to 600 mM salt fractions. With peptide p270523–1281WY (lower panel), 76.2% of
the total counts per minute were recovered in the flowthrough and wash fractions
while 16.7% eluted in the 200 to 600 mM salt fractions.
FIG. 8. DNA binding activity of a GST-p270 fusion peptide. GST fusion
protein GSTp270600–1018 was passed over a DNA cellulose column and collected
in a series of increasing salt fractions as described for Fig. 6. Aliquots of each
fraction were separated on SDS-polyacrylamide gels. The electrophoresed pro-
teins were transferred to nitrocellulose blots, probed with GST-specific antibod-
ies, and visualized by chemiluminescence. The fusion protein eluted primarily in
the 400 mM salt fractions. The sequences encompassed by the fusion peptide are
indicated schematically to the left of the gel.
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ferred to nitrocellulose blots and probed with GST-specific
antibodies. The DNA binding profile of the fusion protein
(Fig. 8) was essentially the same as that seen with the reticu-
locyte lysate-translated peptides shown above. GST alone
passed through the columns and was recovered entirely in the
flowthrough and wash fractions (not shown).
Having verified that the fusion protein binds to DNA, we
used this construct as the basis for the PCR-based selection of
preferred DNA binding sequences. The fusion protein, bound
to glutathione-Sepharose beads, was incubated with a pool of
oligomers containing stretches of 20 random bases. Unbound
oligomers were washed off and the remaining pool was ampli-
fied by PCR. This process was repeated four times, and the
remaining oligomers were cloned and sequenced. In this orig-
inal analysis, unbound oligomers were washed off in 100 mM
NaCl in a standard cyclic amplification and selection proce-
dure. When this protocol failed to reveal any sequence pref-
erence in the final cloning, the procedure was repeated at
higher stringency. In the second protocol unbound oligomers
were washed off in 800 mM NaCl and the process was repeated
through six cycles. Despite this high-stringency selection, the
resulting clones revealed no preference for specific sequences.
The resulting sequences are shown in Fig. 9. Twenty-five inde-
pendent clones were sequenced and yielded 13 unique se-
quences. The overall percentage of A1T residues in the 13
unique sequences is 47.9%. This is only marginally higher than
the AT content of the original oligonucleotide pool, which we
estimate to be 44.0% based on sequences obtained from 16
oligonucleotides cloned without selection from the original
batch (not shown). The selected sequences were analyzed by
the Wisconsin GCG PileUp program to search for similarity,
but no common motifs were discernible.
These results are in sharp contrast to the strong sequence
specificity of DRI. We therefore used EMSAs to compare p270
and DRI directly. The GST-p270600–1018 fusion protein was
compared with the GST-dri258–410 fusion protein, the construct
used to determine DRI specificity. Lane 1 in Fig. 10 shows
GST-p270600–1018 in the absence of poly(dI-dC) shifting a
probe containing the AT-rich, DRI-selected consensus se-
quence (AATTAA). Lanes 2 through 4 show aliquots of the
same reaction mixture incubated with increasing amounts of
cold poly(dI-dC). The poly(dI-dC) competes effectively with
the DRI consensus sequence for binding to the p270 peptide.
Lanes 5 through 8 show the same series of reactions, except
that GST-dri258–410 was used in place of the p270 peptide.
When the DRI-selected sequence is bound to DRI, poly(dI-
dC) does not compete effectively. Lane 9 shows the GST-
p270600–1019 fusion protein binding to a probe corresponding
to clone 18 from the p270 selection. This probe is competed by
poly(dI-dC) as effectively as the probe based on the DRI-
selected sequence (compare lanes 10 to 12 with lanes 2 to 4).
Thus, in direct comparison to DRI, p270 does not show a
specific preference for this AT-rich sequence. Moreover, p270
does not show specific preference for a sequence obtained
from the p270 selection protocol. The DNA binding properties
of p270 indicate that AT preference is not an intrinsic property
of ARID regions. The consensus ARID sequence appears to
specify general DNA binding properties, while any preference
for specific sequences is likely to derive from other residues in
the ARID region.
DISCUSSION
p270 was first recognized through its shared antigenic spec-
ificity with p300 and CBP. Cloning and sequencing p270, how-
ever, reveals that this protein is most closely related to an
emerging family of proteins distinguished by the presence of a
novel DNA binding region, termed ARID. The functions of
ARID proteins as they are understood to date (summarized in
FIG. 9. Sequences of oligonucleotides bound by p270. Shown are sequences
bound by the p270 fusion protein after six cycles of amplification and selection.
The overall percentage of AT residues is 47.9%. The sequences were analyzed by
the Wisconsin GCG PileUp program, but no common motifs were detected.
FIG. 10. p270 shows no sequence preference in an EMSA. The DNA binding
activity of p270 (lanes 1 to 4 and 9 to 12) and DRI (lanes 5 to 8) was assayed by
gel shift using 32P-labeled oligonucleotide probes p270.18 (lanes 1 to 4) and
dri.16 (lanes 5 to 12). Competition assays included unlabeled poly(dI-dC) at a
molar excess of approximately 20:1 (lanes 2, 6, and 10), 140:1 (lanes 3, 7, and 11),
and 600:1 (lanes 4, 8, and 12).
TABLE 1. Proteins with ARID motifsa
Protein(s) Function (reference[s])
Bright .........................B-cell-specific activator (11, 42)
DRI ............................Corepressor for Drosophila dorsal (9, 37); may
function as an activator in other contexts (32)
MRF-1, MRF-2 ........Modulator recognition factors; repressors of
CMV enhancer activity (12, 35, 43)
RBP 1, RBP 2 ..........Retinoblastoma binding proteins (7); RBP 1 is
a repressor of E2F (21, 22)
smcx, smcy.................Sex-specific transcription factors (1, 15)
jumonji.......................Neural tube-specific transcription factor (33)
eyelid..........................Antagonist of Drosophila wingless (36, 38)
SWI1 ..........................Component of yeast SWI-SNF complex (25, 28)
p270............................Component of human SWI-SNF complex (6)
a Partial list of known ARID proteins. A few others are recognizable on the
basis of open reading frames in GenBank sequences but have no known function.
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Table 1) suggest that this family consists of transcriptional
activators, coactivators, and corepressors. Bright and DRI are
the founding members of the ARID family, and both bind to
AT-rich sequences. In agreement with the expectation that the
ARID consensus specifies DNA binding activity, p270 has an
intrinsic ability to bind linear duplex DNA. This activity is
dependent on the integrity of the consensus sequence; replace-
ment of two consensus residues with alanine severely disrupts
the DNA binding activity. However, unlike Bright and DRI,
p270 does not bind preferentially to AT-rich sites; indeed p270
shows no sequence preference in its DNA binding activity. This
property of p270 reveals that the ARID consensus sequence
does not in itself specify a preference for AT-rich DNA. More
likely, a binding site preference, or the lack thereof, is deter-
mined by the nature of the less conserved residues within
ARID regions. It is unlikely that sequence specificity is deter-
mined by residues very distal to the ARID region, because the
sequence specificity of DRI is contained within a 152-residue
peptide (dri258–410) containing only the ARID region and res-
idues closely flanking it (9). Likewise, the sequence specificity
of MRF-2 is contained within a 108-residue peptide encom-
passing only the ARID region (35).
This demonstration that the ARID consensus does not in
itself specify a preference for AT-rich DNA is consistent with
the first structural studies on ARID proteins. Solution struc-
tures have been published for both MRF-2 (46) and DRI (13).
Although the proposed structures differ in some respects, both
are consistent with a wider range of DNA binding activity than
a simple preference for AT-rich sites. The solution structure
for the ARID region of MRF-2 suggests that ARID regions
have features resembling the helices in homeodomains, but it
also indicates that the structure shares a more significant de-
gree of homology with DNA binding proteins such as DNA
replication and repair nucleases and polymerases, which do not
exhibit sequence specificity. The presumptive DNA contact
residues in the ARID structure of DRI (the MKY sequence
immediately following the invariant Y corresponding to posi-
tion 738 in p270) are conserved between Bright and DRI but
are not conserved in ARID proteins generally or in p270. It is
clear from Fig. 4 that the region of high homology between
Bright and DRI extends both N terminally and C terminally to
the core consensus sequence. These “extended” ARID se-
quences appear to define a subgroup within the ARID family
and may contribute to sequence-specific binding (9, 13, 19).
The behavior of p270 yields new insight into the properties of
ARID family members outside the Bright and DRI subgroup.
A general DNA binding function for p270 is more consistent
with the presumptive role of the mammalian SWI-SNF com-
plexes, which have not shown sequence specificity in their
DNA binding. These complexes contain an ATP-dependent
nucleosome remodelling activity that is associated with general
transcriptional activation. The source of the required ATPase
activity in the complex is believed to be BRG1 or other human
members of the yeast SWI2 family. p270 is stably associated
with human SWI-SNF complexes in vivo, as indicated by im-
mune complex isolation with antibodies directed against at
least three different components of the complexes (6). Wang et
al. (39, 40) have also noted a 250-kDa protein band associated
with human SWI-SNF immune complexes. This BRG1-associ-
ated factor (BAF-250) corresponds to p270 based on our eval-
uation of BRG1-associated complexes using the same anti-
bodies (6). Biochemical purification also yields a complex
containing a 250- to 270-kDa protein (hSWI-SNF complex A)
(20). An alternative purification procedure yields a complex
without a 250- to 270-kDa band (HSWI-SNF complex B),
which retains nucleosome remodelling activity in vitro (20, 30).
Thus p270 is not required for this aspect of hSWI-SNF com-
plex function.
The presence of similar proteins, p270 and SWI1, in both
human and yeast SWI-SNF complexes argues that the function
of these proteins is intrinsic to the respective complexes. The
identification of p270 as a member of the emerging family of
ARID-containing proteins suggests that p270 functions as a
coactivator or corepressor, perhaps in combination with nu-
clear hormone receptors, as implied by the presence of the
LXXLL motifs. SWI-SNF complexes are linked with regula-
tion in response to multiple steroid hormone receptors (see,
e.g., references 4, 8, 24, 26, and 45). However, the manner in
which the function of the hSWI-SNF complexes is integrated
with specific transactivation complexes is not at all clear. In a
recent review, Kingston and Narlikar (17) suggested that
hSWI-SNF complexes have a general nucleosome-remodelling
activity that can be upregulated in response to various signals.
This model proposes that the actual activation of any promoter
depends on the presence in the cell of specific transcription
factor complexes, which must gain access to the DNA during
the dynamic process of nucleosome remodelling. The proper-
ties of p270 suggest that a protein with potential coactivator or
corepressor activity is available within the hSWI-SNF complex
to bind to the newly accessible DNA. p270 may play an inter-
mediary role, possibly regulated by interaction with specific
activators, such as nuclear hormone receptors, before true
activation complexes, including such coactivators as p300 and
CBP, are formed at specific promoter sites.
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